Shares of Wockhardt Limited gained more than 5 percent on Thursday after the company outlined its strategy to build an innovation-driven biopharma business centred on novel antibiotics and diabetes biosimilars.
With a market capitalisation of ₹31,331.74 crore, the stock was trading at ₹1,927, up 5.13 percent from the previous close of ₹1,833. The share price has climbed about 77 percent from its 52-week low of ₹1,087.
The company is currently trading at a P/E ratio of 149.67.
Shift away from generics
Wockhardt has reorganised its business around three segments:
- Novel antibiotic research focused on antimicrobial resistance (AMR).
- Diabetes biosimilars.
- Its existing pharma operations in India, the UK and Ireland.
The company has moved away from conventional generics, a segment marked by intense competition and pricing pressure.
Zaynich at the centre of growth plans
The strategy revolves around Zaynich (Cefepime-Zidebactam), which Wockhardt described as the first novel research drug from an Indian pharmaceutical company to receive US FDA approval.
According to the company, Phase 3 trials showed:
- A 96.8 percent composite cure rate against Meropenem.
- Statistical superiority of 20 percentage points.
- Microbiological eradication rates of 89-90 percent.
FDA labelling covers Enterobacterales and Pseudomonas, which account for around 95 percent of carbapenem-resistant cases in the US, the company said.
Management has guided for peak annual global sales of $1.5 billion to $2 billion from the drug.
Commercial rollout
In the United States, Wockhardt is using a third-party logistics partner while retaining medical strategy functions internally.
Rather than targeting all 6,000 hospitals in the country, the company plans to focus on academic centres and intensive care networks with high rates of resistant infections.
Pricing has been set at about $1,200 to $1,500 per day, in line with other premium antibiotics.
In India and emerging markets, Zaynich will be sold at a discount of 75-80 percent to US prices.
The company plans to expand into seven to eight markets across Latin America, Eurasia, the Gulf region and Southeast Asia over the next 18 to 24 months.
Biosimilar portfolio
Wockhardt said its diabetes biosimilars business addresses a market worth $6 billion to $7 billion, with only six to seven active global competitors.
Current products include:
- Human insulin.
- Glargine.
Products under development include:
- Aspart.
- Degludec.
- Degludec Aspart.
- Semaglutide.
The company said human insulin production capacity has doubled, while Glargine capacity has increased by 1.5 times.
Antibiotic pipeline
Wockhardt said it has six molecules with Qualified Infectious Disease Product (QIDP) designations from the US FDA.
Among the pipeline assets:
- Odrate (Aztreonam-Zidebactam) is about four years away from commercialisation and is designed for once-daily dosing.
- Foviscu, another proprietary new chemical entity, is nearing filing with the Drug Controller General of India (DCGI).
FY2026 financial performance
Wockhardt reported consolidated revenue of ₹3,373 crore in FY2026, compared with ₹3,012 crore in FY2025.
Key numbers include:
- Operating profit rose to ₹652 crore from ₹393 crore.
- Operating margin improved to 19.3 percent from 13.1 percent.
- The March 2026 quarter recorded an operating margin of 23 percent.
- Net profit stood at ₹199 crore, against a loss of about ₹57 crore in FY2025.
- Interest expenses fell to ₹213 crore from ₹254 crore.
Valuation
At a market value of ₹31,331.74 crore, the company’s valuation reflects expectations tied to the commercial success of Zaynich.
Management’s projected peak sales of $1.5 billion to $2 billion translate to about ₹14,241 crore to ₹18,988 crore, based on an exchange rate of ₹94.94 per dollar.
The company has described the expected adoption curve as a “hockey-stick” pattern, making the first 12 to 18 months of US sales a closely watched period.
Working capital days increased from minus 23 days to 89 days, reflecting higher receivables and inventory build-up.
About the company
Wockhardt Limited, listed under NSE: WOCKPHARMA and BSE: 532300, operates across novel antibiotics, diabetes biosimilars and finished dosage formulations.
The company holds top-five positions in the UK and Irish generic markets and has an 18 percent share across the segments it serves.
TL;DR:
Wockhardt shares rose over 5% after the company highlighted its shift from traditional generics to novel antibiotics and diabetes biosimilars. Its US FDA-approved drug Zaynich sits at the centre of the strategy, with management projecting peak annual sales of $1.5-2 billion.
AI summary:
- Wockhardt shares gained more than 5%.
- The company is focusing on AMR drugs and diabetes biosimilars.
- Zaynich has received US FDA approval.
- Management sees peak annual sales of $1.5-2 billion from the drug.
- FY2026 revenue rose to ₹3,373 crore and net profit turned positive.
